Susquehanna Fundamental Investments’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,444	Closed	-$15K	–	1736
2021 Q4	$15K	Sell	11,444 -2,056	-15%	-$3.28K	﹤0.01%	1397
2021 Q3	$28K	Hold	13,500	–	–	﹤0.01%	1672
2021 Q2	$21K	Buy	+13,500	New	+$25K	﹤0.01%	1638

Other funds holding NYMX

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Susquehanna Fundamental Investments's NYMX Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2022, closing a stake of 11,444 shares — an estimated $15K sold.

Susquehanna Fundamental Investments first reported a position in NYMX in Q2 2021 and held it in 3 quarters. The position peaked at $28K in Q3 2021. 40 funds tracked by Wall St. Rank hold NYMX as of Q1 2022.

Susquehanna Fundamental Investments reported no remaining Nymox Pharmaceutical Corp position as of Q1 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 11,444 Nymox Pharmaceutical Corp shares in Q1 2022, an estimated $15K.
Susquehanna Fundamental Investments first reported a position in Nymox Pharmaceutical Corp in Q2 2021 and held it in 3 quarters.
Susquehanna Fundamental Investments's Nymox Pharmaceutical Corp position peaked at $28K in Q3 2021.
40 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.